Abstract

Moxifloxacin and Gentamicin are commonly used antibiotics for the treatment of bacterial conjunctivitis, but there is limited evidence comparing their efficacy and safety.Objective: To compare the clinical efficacy and safety of moxifloxacin and gentamicin eye drops in the treatment of bacterial conjunctivitis.Methods: This was a randomized controlled trial (RCT) involving 120 patients with bacterial conjunctivitis. Patients were randomly assigned to receive either moxifloxacin 0.5% eye drops or gentamicin 0.3% eye drops for 7 days. The primary outcome measure was the clinical cure rate on day 7, and secondary outcome measures were time to resolution of symptoms, adverse events, and bacterial culture results.Results: The clinical cure rate was 90% in the moxifloxacin group and 83.3% in the gentamicin group (P=0.37). The mean time to resolution of symptoms was 5.2±1.3 days in the moxifloxacin group and 6.1±1.5 days in the gentamicin group (P=0.03). Adverse events were similar in both groups, with ocular irritation being the most commonly reported adverse event, which was mild and self-limiting. Bacterial culture results showed that both antibiotics had similar coverage against common bacterial pathogens.Conclusion: Both moxifloxacin and gentamicin eye drops are effective and safe in the treatment of bacterial conjunctivitis. Moxifloxacin may result in a faster resolution of symptoms compared to gentamicin. The findings of this study may guide clinicians in choosing appropriate antibiotics for the treatment of bacterial conjunctivitis.

Description